NCT00190242 - Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2003

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2009

Conditions

HIV Infection

Interventions

DRUG

group1

Havrix at 1440IU was administrated à weeks S0, S4 and S24

DRUG

group2

Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS

Trial Locations (2)

CISIH, Hôpital de Strasbourg, Strasbourg

CIC de vaccinologie Cochin Pasteur, Service de médecine interne, hôpital Cochin, Paris